Investment of $36.5 million secured by IXI for advancement of self-focusing spectacle technology
IXI's Autofocus Glasses Revolutionize Prescription Eyewear
In a groundbreaking development for the autofocus glasses market, Finnish startup IXI is leading the charge with its innovative technology. The company, founded in 2021 by a team specializing in wearable technology, optics, and industrial design, has developed a solution that could make traditional presbyopia glasses obsolete [1][2].
IXI's technology uses low-power sensors combined with liquid crystal optics to dynamically adjust the focal length based on where the wearer is looking. This enables real-time personalized vision correction without the need for traditional bifocals or progressive lenses. The autofocus adjustment happens swiftly, within about 0.2 seconds, creating a natural visual experience without lag [1][2].
Sten Tamkivi, Partner at Plural, believes that IXI's advanced optics and eye-tracking solutions will revolutionize how people see the world. He led the $36 million Series A funding round for IXI in April 2025, which also included Amazon and other investors [1][3]. This funding will enable IXI to complete the product development of IXI Adaptive Eyewear and kick off commercial operations.
Tesi, byFounders, Heartcore, Eurazeo, FOV Ventures, Tiny Supercomputer, and IXI's existing investors also participated in the funding round. The funding is intended to accelerate the development and commercialization of IXI's innovative autofocus technology in prescription eyewear [1][3].
IXI is positioned in a growing global eyewear market valued at approximately $200 billion, targeting a large potential user base, especially among people with presbyopia [1][2]. The company aims to redefine advanced vision tech with unique real-time and ultra-low-power eye tracking and state-of-the-art dynamic lens technology.
Meanwhile, in a separate development, researchers at Waseda University have developed a breakthrough in eye wear technology with an advanced contact lens. Additionally, Ceryx Medical has secured $15 million to advance its groundbreaking heart failure technology [1].
These advancements highlight the rapid pace of innovation in various sectors, with companies like IXI pushing the boundaries of traditional eyewear and improving multi-focal vision. The future of prescription eyewear is undoubtedly exciting, and IXI is at the forefront of this evolution.
[1] Medical Device Manufacturing News. (2025). IXI Raises $36 Million for Autofocus Prescription Glasses. [2] Medical Device Manufacturing News. (2025). Waseda University Develop Advanced Contact Lens Technology. [3] Medical Device Manufacturing News. (2025). Ceryx Medical Secures Funding for Heart Failure Technology.
- IXI's innovative autofocus glasses, poised to revolutionize the eyewear market, are led by a Finnish startup specializing in wearable technology, optics, and industrial design.
- With the ability to dynamically adjust focus based on the wearer's gaze, these glasses may render traditional presbyopia glasses obsolete, impacting the health-and-wellness sector.
- The funding of $36 million, contributed by Plural, Amazon, and other investors, will allow IXI to finalize the development of IXI Adaptive Eyewear and initiate commercial operations, accelerating the realization of this personal-finance investment.
- As part of a growing global eyewear market valued at up to $200 billion, IXI aims to lead the advancement in vision technology with real-time eye tracking and dynamic lens technology.
- Concurrently, advancements in technology extend beyond eyewear, with Waseda University introducing an innovative contact lens and Ceryx Medical securing funding for its groundbreaking heart failure technology, showcasing the pace of research and development across various sectors.
